1. Splenomegaly, myeloid lineage expansion and increased osteoclastogenesis in osteogenesis imperfecta murine
   Brya G. Matthews et al, 2017, Bone CrossRef
2. Structural optimization of a TNFR1-selective antagonistic TNFα mutant to create new-modality TNF-regulating biologics
   Masaki Inoue et al, 2020, Journal of Biological Chemistry CrossRef
3. Effects of selective TNFR1 inhibition or TNFR2 stimulation, compared to non-selective TNF inhibition, on (neuro)inflammation and behavior after myocardial infarction in male mice
   L. Gouweleeuw et al, 2021, Brain, Behavior, and Immunity CrossRef
4. TNF is a potential therapeutic target to suppress prostatic inflammation and hyperplasia in autoimmune disease
   Renee E. Vickman et al, 2022, Nature Communications CrossRef
5. Monitoring Therapy Response of Experimental Arthritis with Radiolabeled Tracers Targeting Fibroblasts, Macrophages, or Integrin αvβ3
   Samantha Y.A. Terry et al, 2016, Journal of Nuclear Medicine CrossRef
6. Gene Expression of Tumor Necrosis Factor-Alpha in Etanercept-Treated Rheumatoid Arthritis Patients
   Aseel S. Mahmood et al, 2017, Journal of Biosciences and Medicines CrossRef
7. Possibilities for preventive treatment in rheumatoid arthritis? Lessons from experimental animal models of arthritis: a systematic literature review and meta-analysis
   J S Dekkers et al, 2017, Annals of the Rheumatic Diseases CrossRef
8. A short review of the pharmacokinetic behavior of biological medicinal agents for the clinical practice
   Sandor Kerpel-Fronius, 2018, Microchemical Journal CrossRef
9. Mangiferin alleviates experimental peri-implantitis via suppressing interleukin-6 production and Toll-like receptor 2 signaling pathway
   Hao Li et al, 2019, Journal of Orthopaedic Surgery and Research CrossRef
10. Pharmacological blockade of TNFα prevents sarcopenia and prolongs survival in aging mice
    Clara Sciorati et al, 2020, Aging CrossRef
11. Targeted Therapy for Glomerulonephritis Using Arterial Delivery of Encapsulated Etanercept
    Natalia A. Shushunova et al, 2023, International Journal of Molecular Sciences CrossRef
12. Expression of mBD4, mBD3 and CRAMP during type II collagen-induced arthritis/CIA and their association with inflammation and bone-remodeling markers
    G. Mendez-Frausto et al, 2021, Experimental and Molecular Pathology CrossRef
13. Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients
    Romy Mosch et al, 2022, Frontiers in Immunology CrossRef
14. Mangiferin inhibits lipopolysaccharide-induced production of interleukin-6 in human oral epithelial cells by suppressing toll-like receptor signaling
    Hao Li et al, 2016, Archives of Oral Biology CrossRef
15. Engineered synthetic cell penetrating peptide with intracellular anti‐inflammatory bioactivity: An in vitro and in vivo study
    Jue‐Yeon Lee et al, 2021, Journal of Biomedical Materials Research Part A CrossRef
16. In vivo imaging of activated macrophages by 18F-FEDAC, a TSPO targeting PET ligand, in the use of biologic disease-modifying anti-rheumatic drugs (bDMARDs)
    Seock-Jin Chung et al, 2018, Biochemical and Biophysical Research Communications CrossRef
17. A Synthetic Cell-Penetrating Heparin-Binding Peptide Derived from BMP4 with Anti-Inflammatory and Chondrogenic Functions for the Treatment of Arthritis
    Da Hyeon Choi et al, 2020, International Journal of Molecular Sciences CrossRef
18. TGF‐β‐activated kinase‐1 inhibitor LL‐Z1640‐2 reduces joint inflammation and bone destruction in mouse models of rheumatoid arthritis by inhibiting NLRP3 inflammasome, TACE, TNF‐α and RANKL expression
    Hirofumi Tenshin et al, 2022, Clinical & Translational Immunology CrossRef
19. Alteration of the gut microbiota in tumor necrosis factor‐α antagonist‐treated collagen‐induced arthritis mice
    Binglong Wang et al, 2020, International Journal of Rheumatic Diseases CrossRef